Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRPF1 | P55201 | 1/20 | 0.40 |
| ▸ | HSD17B3 | P37058 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | BRD4 | O60885 | 2/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.30 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.30 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.30 |
| ▸ | OGFRL1 | Q5TC84 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28297314 | 0.84 | AVPR1A (0.38) | BRPF1HSD17B3GAAMEN1KMT2A | |
| SCHEMBL11844055 | 0.74 | TGM2 (0.38) | BRPF1HSD17B3GAASMN1; SMN2 | |
| SCHEMBL4076384 | 0.73 | BRPF1 (0.42) | BRPF1HSD17B3GAAMEN1KMT2A | |
| SCHEMBL8039565 | 0.69 | BRPF1 (0.39) | BRPF1HSD17B3GAAMEN1KMT2A | |
| SCHEMBL2690960 | 0.67 | BRPF1 (0.40) | BRPF1HSD17B3GAAMEN1KMT2A | |
| SCHEMBL1383225 | 0.67 | ALDH1A1 (0.44) | GAAMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL9521938 | 0.66 | BRPF1 (0.41) | BRPF1HSD17B3GAAMEN1KMT2A | |
| SCHEMBL17114712 | 0.66 | BRPF1 (0.41) | BRPF1HSD17B3GAAMEN1KMT2A | |
| SCHEMBL21400260 | 0.66 | BRPF1 (0.41) | BRPF1HSD17B3GAAMEN1KMT2A | |
| SCHEMBL4265285 | 0.66 | BRPF1 (0.41) | BRPF1HSD17B3GAAMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200237754-A1 | TUBULIN BINDING COMPOUNDS AND THERAPEUTIC USE THEREOF | BEYONDSPRING PHARMACEUTICALS, INC. | 2020-07-30 | — | — | US | disclosed |
| US-20070072912-A1 | Alicyclic-amine-substituted 4-carboxamido-benzimidazoles as parp-inhibitors and antioxidants | CEDARS-SINAI MEDICAL CENTER (US) | 2007-03-29 | — | — | US | disclosed |
| EP-1622893-A1 | NEW ALICYCLIC-AMINE-SUBSTITUTED 4-CARBOXAMIDO-BENZIMIDAZOLES AS PARP-INHIBITORS AND ANTIOXIDANTS | Hideg, Kalman (HU) | 2006-02-08 | — | — | EP | disclosed |
| WO-2004096793-A1 | NEW ALICYCLIC-AMINE-SUBSTITUTED 4-CARBOXAMIDO-BENZIMIDAZOLES AS PARP-INHIBITORS AND ANTIOXIDANTS | HIDEG KALMAN (HU) | 2004-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070072912-A1 | Alicyclic-amine-substituted 4-carboxamido-benzimidazoles as parp-inhibitors and antioxidants | PARP1, PARP2, PARP11 | BRPF1 2806/4885HSD17B3 2876/4885GAA 2359/4885 |
| US-20200237754-A1 | TUBULIN BINDING COMPOUNDS AND THERAPEUTIC USE THEREOF | TUBB6, TUBB1, TUBB | BRPF1 940/4885HSD17B3 4206/4885GAA 496/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.